Role of Combination Therapy in Women With Refractory Overactive Bladder

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · May 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for women with a condition called refractory overactive bladder (OAB), which makes them feel a sudden, strong urge to urinate, often leading to accidents. The trial will look at whether combining a medication called vibegron with a procedure known as intradetrusor onabotulinumtoxinA injections can provide better relief for patients compared to using the injections alone. The goal is to find a more effective and less invasive option for women who haven't had success with other treatments.

To participate in this trial, women must be at least 18 years old and undergoing the botulinum injections for their OAB. They should also be comfortable reading and speaking English and able to give their consent to join the study. However, women who are allergic to vibegron, pregnant, breastfeeding, or taking a specific heart medication called digoxin will not be eligible. If women join the trial, they can expect to receive either the combination treatment or just the injections while contributing to important research that could improve future OAB therapies.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Women undergoing intradetrusor botulinum injections for refractory OAB
• • 2. Age 18 years old or greater
• • 3. Fluency and literacy in English
• • 4. Capacity to provide consent
• Exclusion Criteria:
• • 1. Allergy to Vibegron
• • 2. Currently pregnant or planning to become pregnant
• • 3. Breastfeeding
• • 4. Current digoxin use